Treatments for newly diagnosed multiple myeloma: when endurance is interrupted

Kumar Shaji K.; Jacobus Susanna J.; Rajkumar S. Vincent

首页> 外文期刊>The lancet oncology >Treatments for newly diagnosed multiple myeloma: when endurance is interrupted

【24h】

Treatments for newly diagnosed multiple myeloma: when endurance is interrupted

机译：新诊断的多发性骨髓瘤的治疗：当耐力中断时

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2020年第12期|共1页
作者
Kumar Shaji K.; Jacobus Susanna J.; Rajkumar S. Vincent;
展开▼
作者单位

Mayo Clin Div Hematol Rochester MN 55905 USA;

Dana Farber Canc Inst ECOG ACRIN Biostat Ctr Boston MA 02115 USA;

Mayo Clin Div Hematol Rochester MN 55905 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment [J] . Guangzhong Yang, Wenming Chen, Yin Wu 中国癌症研究（英文版） . 2013,第002期
2. The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment [J] . 李菲中国医学文摘：内科学分册（英文版） . 2013,第004期
3. Competing endogenous RNA network in newly diagnosed multiple myeloma by genetic microarray [J] . Yu-Qin He, Zhi-Yao Zhang, Hui-Xing Zhou, 中华医学杂志（英文版） . 2020,第021期
4. Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China [J] . Yu-Ping Zhong, Yi-Zhuo Zhang, Ai-Jun Liao, 中华医学杂志（英文版） . 2017,第002期
5. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted [J] . Landgren Ola, Siegel David, Kazandjian Dickran, The lancet oncology . 2020,第12期

机译：新诊断的多发性骨髓瘤的治疗：当耐力中断时
6. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial [J] . Kumar Shaji K., Jacobus Susanna J., Cohen Adam D., The lancet oncology . 2020,第10期

机译：Carfilzomib或Bortezomib与Lenalidomide和地塞米松组合，用于新诊断的多骨瘤的患者，无需立即自体干细胞移植（耐久性）：多期，开放标签，第3阶段，随机，受控试验
7. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. [J] . Dispenzieri A, Rajkumar SV, Gertz MA, Mayo Clinic Proceedings . 2007,第3期

机译：基于骨髓瘤的梅奥分层和适应风险的疗法（mSMART）治疗新诊断的多发性骨髓瘤：共识声明。
8. Interphase FISH of Chromosome 1 and 13 in Newly Diagnosed Myeloma and the Disease Prognosis [C] . Tian, Erming, Borset, Magne, Barlogie, Bart, International Conference on Biomedical Engineering and Informatics;BMEI '09 . 2009

机译：新诊断骨髓瘤的染色体1和13的相间FISH及疾病预后
9. Mutation, SNP and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. [D] . Onwuazor, Obiageli Nneka. 2003

机译：150名新诊断的多发性骨髓瘤患者的成纤维细胞生长因子受体3（FGFR3）的突变，SNP和同工型分析。
10. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma [O] . Monika Engelhardt, Evangelos Terpos, Martina Kleber, 2014

机译：欧洲骨髓瘤网络对新诊断多发性骨髓瘤患者的评估和治疗建议
11. MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia [O] . Sarah Brown, Debbie Sherratt, Samantha Hinsley, 2021

机译：Muknine最佳方案：一种筛选研究，用于鉴定适用于新型治疗方法的多发性骨髓瘤患者的筛查研究，所述方法结合了新诊断的高风险多发性骨髓瘤和血浆细胞白血病的生物治疗优化组合的研究
12. Facilitating Treatment Decision Making, Adjustment, and Coping in Men Newly Diagnosed with Prostate Cancer. Addendum [R] . Diefenbach, M. A. , Miller, S. M. 2005

机译：促进新诊断为前列腺癌的男性的治疗决策，调整和应对。附录

Treatments for newly diagnosed multiple myeloma: when endurance is interrupted

著录项

相似文献

相关主题

期刊订阅